A Medical Device Daily
Quick-Med Technologies (Gainesville, Florida) and Avery Dennison (Pasadena, California) reported that they entered into a joint development and exclusive option agreement to collaborate in applying Quick-Med's Nimbus technology to adhesives for medical device and industrial applications.
"We are excited to team with Avery Dennison to incorporate our advanced Nimbus technology in adhesives," said J. Ladd Greeno, CEO of Quick-Med Technologies. "Avery Dennison is the respected leader in developing advanced adhesives to meet the requirements of medical device manufacturers. This collaboration will leverage Nimbus technology to a next generation of antimicrobial adhesives to address growing infection concerns."
"Our partnership with Quick-Med will enable us to bring innovative, next-generation antimicrobial technology to meet the needs of both existing and potential customers," said Kevin Young, vice president & general manager of Avery Dennison. "Nimbus technology will continue Avery Dennison innovation firsts by bringing much needed, uniquely effective and affordable, non-leaching antimicrobial protection to applications for the medical devices market."
What makes Nimbus different from other antimicrobial technology is its permanent bond and its ability to be effective even in the presence of large amounts of serum and body fluids. The active agent is permanently bonded to the substrate, keeping the biocide from depletion or leaching antimicrobials into the wound, while killing microbes (such as MRSA, VRE, and many others) that are present on the device. Being bound to the substrate keeps the antimicrobial at full strength; test results show that even in 90% serum, Nimbus continues to kill microbes outperforming other antimicrobials.
In other agreements/contracts news:
• deCODE genetics (Reykjavik, Iceland) and Celera (Alameda, California) have signed agreements under which deCODE has granted Celera non-exclusive worldwide licenses to deCODE's genetic markers for increased risk of major cardiovascular and metabolic diseases, including heart attack, stroke, atrial fibrillation and type 2 diabetes. These markers can be incorporated into laboratory tests for assessing and managing individual risk of these diseases.
"This is an excellent opportunity to broaden the clinical application and commercialization of our discoveries of high-impact genetic risk factors for major diseases. The markers included in these agreements are among the most widely replicated genetic risk factors for cardiovascular and metabolic disease, and they provide a natural complement to the biomarker services already offered by Berkeley HeartLab, Celera's subsidiary. In Celera we have a partner with a global reputation in human genetics and a large and effective outreach and sales force. We are pleased to have the chance to work with them to build upon our discovery and testing platforms and to accelerate the adoption of personalized medicine," said Kari Stefansson CEO of deCODE.
• Magnet Cooperative (Atlanta), one of the largest non-profit group purchasing organizations in the U.S., has signed a sole-source agreement with Elekta (Stockholm, Sweden), enabling its members to begin purchasing Elekta's oncology delivery systems.